Comparative Pharmacology
Head-to-head clinical analysis: CETIRIZINE versus EVALOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CETIRIZINE versus EVALOSE.
Cetirizine vs EVALOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine is a selective second-generation H1-receptor antagonist that inhibits histamine release from mast cells and basophils, thereby reducing allergic symptoms.
EVALOSE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity by blocking the reuptake of serotonin at the presynaptic neuron, thereby increasing serotonin levels in the synaptic cleft.
10 mg orally once daily; 5 mg orally once daily for mild symptoms
Adults: 1-2 tablets (5-10 mg) orally once daily, adjusted to maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 8.3 hours in healthy adults; extended to 20 hours in elderly and patients with renal impairment
Clinical Note
moderateCetirizine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Cetirizine is combined with Fluticasone propionate."
Clinical Note
moderateLevocetirizine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Levocetirizine."
Clinical Note
moderateLevocetirizine + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Levocetirizine."
Clinical Note
moderateLevocetirizine + Cyclosporine
Terminal elimination half-life is 12 hours (range 10-14 h); clinically significant for once-daily dosing in most patients with normal renal function; extend dosing interval in renal impairment
Primarily renal (60% unchanged in urine); minor biliary/fecal (10%)
Renal: 70% unchanged; Biliary/Fecal: 20% as metabolites; 10% other
Category A/B
Category C
Antihistamine
Antihistamine
"The metabolism of Cyclosporine can be decreased when combined with Levocetirizine."